Increasing Shared Decision-Making and Education on Emerging Hemophilia Therapies
Welcome to the dedicated section for our hemophilia education initiative, generously funded by Pfizer and Genmab. This project aims to empower healthcare professionals and patients by increasing awareness of emerging therapies for hemophilia and promoting shared decision-making (SDM).
What We’re Doing
As hemophilia treatments rapidly evolve, we aim to ensure that healthcare providers and patients have the tools and knowledge to make informed decisions. Our approach includes:
- Educating healthcare professionals on cutting-edge therapies, including genetic therapies and rebalancing strategies.
- Promoting shared decision-making to enhance patient engagement and collaboration in care decisions.
- Reaching underserved communities with culturally tailored, accessible resources to address healthcare disparities.
Current Progress
We collect survey responses from healthcare professionals and community members to gain insights into knowledge gaps, confidence levels, and barriers to implementing SDM.
Take the Survey
Your input is invaluable if you are a healthcare professional or community member. By sharing your experiences and insights, you can help shape the future of hemophilia care.
Why It Matters
Hemophilia is a complex condition, and emerging therapies offer new hope for improved outcomes. Education and collaboration are key to ensuring these advancements are accessible and effective for everyone—particularly in underserved communities. Together, we can bridge the gaps in care, empower patients, and foster a more inclusive healthcare landscape.